Used in solid-phase peptide synthesis as a protected amino acid building block, particularly for incorporating sterically hindered and fluorinated side chains into peptide structures. The Fmoc group allows for mild base deprotection, making it compatible with Fmoc-strategy synthesis. The 3,5-difluorophenyl moiety enhances peptide lipophilicity and metabolic stability, which is beneficial in medicinal chemistry for improving bioavailability and target binding affinity. Commonly applied in the development of bioactive peptides, enzyme inhibitors, and peptidomimetics, especially in pharmaceutical research targeting CNS disorders and oncology. Its structural features also support studies on conformation-activity relationships in peptide design.